Eli Lilly’s retatrutide weight loss trial achieved up to 30.3% body weight reduction, matching bariatric surgery. Phase 3 TRIUMPH-1 data, mechanism, and access analysis.
Evidence-based review of intermittent fasting for obesity, type 2 diabetes, CVD, NAFLD, neurodegeneration, and cancer. Safety, protocols, and who should avoid IF.
Evidence for lion’s mane (cognition), reishi (immune, cancer QoL), and chaga (antioxidants). Safety: bleeding risk, liver toxicity, kidney damage.
The FDA just approved Eli Lilly’s Foundayo weight-loss pill. Discover how this restriction-free, $149 daily oral GLP-1 will change global obesity care.
